Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 9/20 | 0.72 |
| ▸ | BRD4 | O60885 | 1/20 | 0.63 |
| ▸ | WDR5 | P61964 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30565215 | 0.85 | PGR (0.75) | PGRBRD4MAPTHSD17B2PKM | |
| SCHEMBL1403074 | 0.85 | PGR (0.75) | PGRBRD4MAPTHSD17B2PKM | |
| SCHEMBL94971 | 0.84 | PGR (0.65) | PGRBRD4WDR5HSD17B2PKM | |
| SCHEMBL1489068 | 0.84 | PGR (0.65) | PGRBRD4WDR5MAPTHSD17B2 | |
| SCHEMBL1859217 | 0.84 | PGR (0.68) | PGRBRD4MAPTHSD17B2PKM | |
| SCHEMBL14434538 | 0.84 | CYP19A1 (0.78) | PGRWDR5CES1HSD17B2CYP19A1 | |
| SCHEMBL28121844 | 0.84 | PKM (0.72) | PGRBRD4MAPTHSD17B2PKM | |
| SCHEMBL4882757 | 0.83 | PGR (0.72) | PGRBRD4WDR5MAPTHSD17B2 | |
| SCHEMBL14433749 | 0.83 | HSD17B2 (0.66) | PGRBRD4WDR5HSD17B2PKM | |
| SCHEMBL28400969 | 0.82 | PGR (0.76) | PGRMAPTCES1PKMCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | MAXYMUNE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | Maxymune Therapeutics, Inc. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS LLC (US) | 2020-09-24 | — | — | US | disclosed |
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | ANTIDOTE IP HOLDINGS LLC (US) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339388-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | PGR 4386/4885BRD4 4379/4885WDR5 2944/4885 |
| US-12427124-B1 | Phenylalanine-based LAT1 inhibitors and uses thereof | SLC43A1, SLC7A1, SLC1A5 | PGR 4386/4885BRD4 4379/4885WDR5 2944/4885 |
| US-20250319046-A1 | PHENYLALANINE-BASED LAT1 INHIBITORS AND USES THEREOF | SLC43A1, SLC7A1, SLC1A5 | PGR 4386/4885BRD4 4379/4885WDR5 2944/4885 |
| US-20200299282-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | VHL, TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | PGR 1488/4885BRD4 472/4885WDR5 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.